Shares of Aptinyx Inc (NASDAQ:APTX) have been given an average rating of “Buy” by the six research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $18.80.
A number of equities research analysts recently commented on APTX shares. Cantor Fitzgerald restated a “buy” rating and set a $40.00 price target on shares of Aptinyx in a research report on Wednesday, January 16th. BMO Capital Markets decreased their price target on Aptinyx to $18.00 and set an “outperform” rating on the stock in a research report on Friday, January 18th. JPMorgan Chase & Co. lowered Aptinyx from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $30.00 to $8.00 in a research report on Thursday, January 17th. Leerink Swann reduced their price objective on Aptinyx from $35.00 to $22.00 and set an “outperform” rating on the stock in a report on Thursday, January 17th. Finally, Zacks Investment Research raised Aptinyx from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a report on Monday, January 21st.
NASDAQ APTX opened at $4.06 on Tuesday. Aptinyx has a one year low of $4.04 and a one year high of $32.25.
Large investors have recently bought and sold shares of the business. Great West Life Assurance Co. Can acquired a new position in Aptinyx during the 4th quarter worth $40,000. Legal & General Group Plc acquired a new position in shares of Aptinyx in the 3rd quarter valued at $58,000. Strs Ohio acquired a new position in shares of Aptinyx in the 3rd quarter valued at $110,000. Metropolitan Life Insurance Co. NY lifted its stake in shares of Aptinyx by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock valued at $120,000 after purchasing an additional 5,652 shares during the period. Finally, Barclays PLC lifted its stake in shares of Aptinyx by 87.1% in the 4th quarter. Barclays PLC now owns 9,323 shares of the company’s stock valued at $154,000 after purchasing an additional 4,340 shares during the period. 63.11% of the stock is currently owned by hedge funds and other institutional investors.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Featured Story: Why are percentage gainers important?
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.